Physician profile
David Serur
NPI 1023070851
$10,579.86
in general payments reported to CMS, 2019-2025
9 companies · $32.30 in 2025
The $32.30 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $149 · 2023: $8,259 · 2024: $191 · 2025: $32.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,852 · Travel and Lodging: $1,025 · Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,852.00 |
| Travel and Lodging | $1,024.76 |
| Food and Beverage | $606.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $8,259.37 | 2023 | |
| Vifor Pharma, INC. | $1,500.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $197.04 | 2019 | |
| Dilon Technologies, INC. | $172.51 | 2024 | Hemoblast Bellows |
| Veloxis Pharmaceuticals, INC. | $167.72 | 2020-2025 | Envarsus |
| Astrazeneca Pharmaceuticals Lp | $129.46 | 2019 | |
| Genzyme Corporation | $120.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.86 | 2024 | Livtencity |
| Merck Sharp & Dohme LLC | $13.95 | 2025 | Prevymis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Serur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.